Literature DB >> 15155181

The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.

Maureen K Bolon1, Sharon B Wright, Howard S Gold, Yehuda Carmeli.   

Abstract

Case-control analyses of resistant versus susceptible isolates have implicated fluoroquinolone exposure as a strong risk factor for fluoroquinolone-resistant isolates of Enterobacteriaceae. We suspect that such methodology may overestimate this association. A total of 84 cases with fluoroquinolone-resistant isolates and 578 cases with fluoroquinolone-susceptible isolates of Escherichia coli or Klebsiella pneumoniae were compared with 608 hospitalized controls in parallel multivariable analyses. For comparison of previous estimates, the results of 10 published case-control studies of risk for fluoroquinolone resistance in isolates of Enterobacteriaceae were pooled by using a random-effects model. Exposure to fluoroquinolones was significantly positively associated with fluoroquinolone resistance (odds ratio [OR], 3.17) and negatively associated with fluoroquinolone susceptibility (OR, 0.18). Multivariable analyses yielded similar estimates (ORs, 2.04 and 0.10, respectively). As data on antibiotic exposure were limited to inpatient prescriptions, misclassification of fluoroquinolone exposure in persons who received fluoroquinolones as outpatients may have led to an underestimation of the true effect size. Pooling the results of previously published studies in which a direct comparison of fluoroquinolone-resistant and fluoroquinolone-susceptible cases was used resulted in a markedly higher effect estimate (OR, 18.7). Had we directly compared resistant and susceptible cases, our univariate OR for the association between fluoroquinolone use and the isolation of resistant Enterobacteriaceae would have been 19.3, and the multivariate OR would have been 16.5. Fluoroquinolone use is significantly associated with the isolation of fluoroquinolone-resistant Enterobacteriaceae; however, previous studies likely exaggerated the magnitude of this association.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155181      PMCID: PMC415612          DOI: 10.1128/AAC.48.6.1934-1940.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Geographical distribution of quinolone resistance among Staphylococcus aureus, Escherichia coli and Klebsiella spp. isolates from 20 European university hospitals. SENTRY Participants Group.

Authors:  F J Schmitz; J Verhoef; A Fluit
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

2.  Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa.

Authors:  A Harris; C Torres-Viera; L Venkataraman; P DeGirolami; M Samore; Y Carmeli
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

3.  Bacteriuria with Escherichia coli resistant to ciprofloxacin in patients with spinal-cord injury.

Authors:  E A Gimber; M D Shields; H N Canawati; F L Sapico; A Krishnaswamy; R El-Farra; K N Maeder; J Z Montgomerie
Journal:  Infect Control Hosp Epidemiol       Date:  1998-02       Impact factor: 3.254

4.  The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable.

Authors:  M J Bonten; S Slaughter; A W Ambergen; M K Hayden; J van Voorhis; C Nathan; R A Weinstein
Journal:  Arch Intern Med       Date:  1998-05-25

5.  Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.

Authors:  J Ortiz; M C Vila; G Soriano; J Miñana; J Gana; B Mirelis; M T Novella; S Coll; M Sábat; M Andreu; G Prats; R Solá; C Guarner
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

6.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

Authors:  J W Warren; E Abrutyn; J R Hebel; J R Johnson; A J Schaeffer; W E Stamm
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

7.  Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.

Authors:  J Ena; C Amador; C Martinez; V Ortiz de la Tabla
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

8.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.

Authors:  J Carratalá; A Fernández-Sevilla; F Tubau; M Callis; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

10.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more
  13 in total

1.  Resistant plasmid profile analysis of multidrug resistant Escherichia coli isolated from urinary tract infections in Abeokuta, Nigeria.

Authors:  O Akingbade; S Balogun; D Ojo; P Akinduti; P O Okerentugba; J C Nwanze; I O Okonko
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections.

Authors:  U Frank; E M Kleissle; F D Daschner; L Leibovici; M Paul; S Andreassen; H C Schonheyder; R Cauda; E Tacconelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

3.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.

Authors:  James A Karlowsky; Daryl J Hoban; Melanie R Decorby; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

6.  Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia.

Authors:  Chun-Hsing Liao; Po-Ren Hsueh; George A Jacoby; David C Hooper
Journal:  J Antimicrob Chemother       Date:  2013-08-16       Impact factor: 5.790

7.  Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision.

Authors:  Ying Wang; Xinping Zhang; Xuemei Wang; Xiaoquan Lai
Journal:  Infect Drug Resist       Date:  2021-08-31       Impact factor: 4.003

8.  Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.

Authors:  Alison H Skalet; Vicky Cevallos; Berhan Ayele; Teshome Gebre; Zhaoxia Zhou; James H Jorgensen; Mulat Zerihun; Dereje Habte; Yared Assefa; Paul M Emerson; Bruce D Gaynor; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Med       Date:  2010-12-14       Impact factor: 11.069

9.  Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.

Authors:  Pudjo H Widjajanto; Sumadiono Sumadiono; Jacqueline Cloos; Ignatius Purwanto; Sutaryo Sutaryo; Anjo Jp Veerman
Journal:  J Blood Med       Date:  2013-02-01

10.  Antimicrobial-resistant invasive Escherichia coli, Spain.

Authors:  Jesús Oteo; Edurne Lázaro; Francisco J de Abajo; Fernando Baquero; José Campos
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.